On-Demand Webinar: Psychedelics Drug Development: Navigating the Science, Regulatory & Outsourcing Landscape

Over the past decade, there has been a surge of interest in psychedelics as a novel treatment choice for mental health conditions including depression and post-traumatic stress disorder (PTSD) as well as for CNS conditions. 

Psychedelics are a class of psychoactive substances that produce changes in perception, mood, and cognitive processes. Growing evidence from scientific studies suggests that treatments that include a psychedelic such as psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), ketamine derivatives and 3,4-methylenedioxymethamphetamine (MDMA) could provide new choices for doctors and their patients to treat these conditions due to targeting different areas of the brain that current methods do not access.

Watch our speakers Richard Castledine, Alan McNeill, and Mark Anstiss as they delve into the many challenges faced in the development of psychedelic APIs, derivatives, and analogues. Our speakers explain how our team can support API development to reach your program milestones in this exciting and fast-moving area.

Key takeaways:

• How the development landscape has evolved with a recent resurgent interest in psychedelic compounds
• How to address challenges around scale up and ¹⁴C synthesis of psychedelic compounds
• How to operate compliantly with these compounds, and the related EH&S, legal, and regulatory considerations that must be considered
• How we have applied our experience to compounds derived from/related to cannabinoids, psilocybin and ketamine to the development of new therapies